Hui-Yun Tseng1, Yi-Ting Tsai2, Ying-Shiuan Su2, Po-Pei Peng2, Gwo-Hwa Wan This email address is being protected from spambots. You need JavaScript enabled to view it.2,3,4,5

1 Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei City, Taiwan
2 Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan, Taiwan
3 Department of Obstetrics and Gynaecology, Taipei Chang Gung Memorial Hospital, Taipei, Taiwan
4 Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan
5 Center for Environmental Sustainability and Human Health, Ming Chi University of Technology, Taishan, New Taipei City, Taiwan


Received: November 5, 2023
Revised: January 9, 2024
Accepted: February 4, 2024

 Copyright The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are cited.


Download Citation: ||https://doi.org/10.4209/aaqr.230265  

  • Download: PDF


Cite this article:

Tseng, H.Y., Tsai, Y.T., Su, Y.S., Peng, P.P., Wan, G.H. (2024). Drug Concentrations in the Air and their Influencing Factors in a Pediatric Intensive Care Unit. Aerosol Air Qual. Res. 24, 230265. https://doi.org/10.4209/aaqr.230265


HIGHLIGHTS

  • VOC concentration in the intensive care unit exceeded the national standard.
  • Acetylcysteine concentration in the air was correlated with CO2 levels.
  • The drug concentration in the air decreased as the distance increased.
  • Maintaining a safe distance is crucial for minimizing drug exposure.
 

ABSTRACT


Aerosolized drug therapy is a common approach in treating respiratory diseases in clinical practice. This study aimed to assess air quality in the pediatric intensive care unit (PICU) of the medical center and investigate variations in drug concentration relative to the patient’s position during aerosolized drug treatment. To monitor air quality and aerosolized drug concentrations in the PICU, we conducted bi-weekly 24-hour samplings over a month. Monitored air quality parameters included temperature, relative humidity (RH), carbon dioxide (CO2), particulate matter (PM), total volatile organic compounds (TVOCs), and aerosolized drug levels in the air. The study also used a small volume nebulizer (SVN) to analyze the relationship between aerosolized drug concentration and distance from a simulated patient. This study revealed that the average concentrations of CO2, PM10 (an aerodynamic diameter equal to or less than 10 µm), and PM2.5 (an aerodynamic diameter less than 2.5 µm) in the PICU met Taiwan’s Ministry of Environment (MOENV) indoor air quality standards. However, the hourly average concentration of TVOCs in the PICU was almost twice the MOENV standard. The concentration of acetylcysteine in the air showed a positive association with both RH and CO2 concentration. Additionally, drug concentrations measured at 1 m, 1.6 m, and 3 m from the SVN were significantly lower than those measured at 0.1 m from the SVN. Continuous monitoring of TVOCs and CO2 in the PICU is necessary. During aerosol therapy, it is crucial for medical staff and family members to maintain a safe distance or integrate a HEPA (high-efficiency particulate air) filter into the ventilator circuit system. This precautionary step aims to minimize unwarranted exposure and maintain hospital air quality.


Keywords: Hospital, Air quality, Particulate matter, Volatile organic compound, Airborne drug, Aerosol therapy


1 INTRODUCTION


Aerosolized drug therapy is a prevalent method used in the treatment of respiratory diseases. The goal of aerosolized drug therapy is to deliver drug-containing particles, generated by a nebulizer, to the respiratory tract and deposit them at the intended target sites. Factors that influence the dosage of inhaled drugs include the type of drug, inspiratory time (Bauer et al., 2009), inspiratory flow, inspiratory-expiratory ratio (Pedersen et al., 2006), type of inhaler (Saeed et al., 2017), type of interface (McGrath et al., 2019), use of a heated humidifier (Yang et al., 2018), and nebulizer setting mode during ventilation (Wan et al., 2014). 

An in vitro study was conducted to investigate the inhalation dose of aerosolized drugs, revealing that approximately 40% of the albuterol drug was deposited in the nebulizer or released into the indoor air (Ari et al., 2016). Concurrently, factors such as the size of the drug storage chamber (holding chamber) (Abdelrahman et al., 2020) and the design of the exhalation hole on the aerosol mask also play a role in influencing the quantity of drug escape (Hui et al., 2014). Furthermore, during drug inhalation, particles smaller than 1 µm were expelled when the patient exhales (Clara et al., 2023). The literature underscores that escaped aerosolized drugs, sputum expulsion, and cleaning activities constituted the primary sources of airborne particulates in the PICU. Notably, these particulates have been observed to rapidly disseminate to other areas (He et al., 2017). The exposure concentration of aerosolized drugs among individuals in close proximity to a patient employing such treatment is influenced by factors such as the air exchange rate, the proximity between the patient and the medical staff during drug inhalation, the patient’s inspiratory flow, and the type of protective masks worn by individuals (Oilier et al., 2019).

During the administration of aerosolized drug treatments, the escape of these drugs can increase the risk of unintended drug exposure for medical personnel and individuals in their vicinity (Saeed et al., 2017; Tsai et al., 2015), potentially leading to health hazards. Research indicates that anticancer drugs, such as cyclophosphamide, 5-fluorouracil, cisplatin, bleomycin, and doxorubicin, can induce genetic damage in surrounding exposed workers (Roussel et al., 2019). Moreover, medical staff exposed to anticancer drugs face an elevated risk of breast and rectal cancer (Ratner et al., 2010). Furthermore, exposure to aerosolized medications, such as Atrovent®, Budesonide, and salbutamol sulfate commonly used in asthma and COPD (chronic obstructive pulmonary disease) treatments, can result in bronchospasm and anaphylaxis in healthcare workers (Chang et al., 2020; Dubus et al., 2003). The risk of occupational asthma among healthcare workers was also found to be associated with their exposure to aerosolized drugs (Delclos et al., 2007).

Until now, there have been limited studies examining drug concentrations in hospital air and investigating variations in drug concentration at different distances from a patient undergoing aerosolized drug therapy. Therefore, in addition to conducting air quality assessments within the PICU of the medical center to understand the distribution of drug concentrations in the air, we conducted additional in vitro experiments. These experiments aimed to explore changes in drug concentration at different positions relative to the patient during aerosolized drug treatment, representing a crucial step toward improving hospital air quality.

 
2 METHODS


 
2.1 Air Quality Monitoring in the PICU

This study was conducted in the PICU of a medical center in northern Taiwan. Air sampling locations included the nursing station and the walkway outside the ward, with the primary consideration being to avoid disrupting personnel entering and exiting. These sampling locations are illustrated in Fig. 1. To monitor changes in air quality and aerosolized drug concentrations in the PICU, we conducted sampling twice a week over the course of a month, with each sampling period lasting 24 hours. All sampling instruments were positioned at a height of 1.2–1.5 meters to simulate the breathing zone of humans. Additionally, sampling instruments were placed at least 45 cm away from walls and other samplers to prevent interference.

Fig. 1. The layout of the pediatric intensive care unit.Fig. 1. The layout of the pediatric intensive care unit.

In this study, we utilized a suspended particulate analyzer (Grimm 1.109, Ainring, Germany) to measure concentrations of PM10, PM2.5, PM1 (an aerodynamic diameter less than 1 µm), and PM≥0.5 (an aerodynamic diameter equal to or larger than 0.5 µm). Furthermore, we employed a nanoparticle counter (NanoTracer XP, Eindhoven, Netherlands) to monitor PM0.01-0.3 (an aerodynamic diameter between 0.01 µm and 0.3 µm) concentration variability. Temperature, RH, and CO2 concentrations within the PICU were analyzed using an indoor air quality monitoring instrument (TSI 7575, Shoreview, US), along with a portable volatile organic gas meter (ppbRAE 3000, San Jose, US) to measure TVOC concentrations.

In addition, this study employed a three-piece cassette containing a polytetrafluoroethylene filter to sample aerosolized drugs in the air, which included bronchodilators (terbutaline and Combivent®), expectorant (acetylcysteine), antibiotics (colistin), and vasoconstrictor (epinephrine).

The sampling flow rate was set at 10 liters per minute (L min–1). To understand the correlation between the concentration of aerosolized drugs in the air and changes in air quality, this study recorded the types and times of aerosolized drug treatments performed on the day of sampling. Filter paper samples were immediately transported to the laboratory and stored at –80°C in a freezer after air sampling. Subsequent drug analysis was conducted as quickly as possible. All filter samples were extracted with sterile deionized water and analyzed using a full-spectrum spectrophotometer (Model SpectraMax Paradigm, San Jose, US) under optimal absorption wavelength conditions. These optimal conditions were as follows: terbutaline: 273 nm, Combivent®: 276 nm, acetylcysteine: 260 nm, colistin: 242 nm, and epinephrine: 260 nm. In cases where the analyzed drug concentration fell below the detection limit, the actual concentration of the sample was estimated by dividing the lowest detected concentration by 2 (Failla et al., 2006).

 
2.2 Analysis of Drug Concentrations in a Simulation Experiment within a Demonstration Ward

This study employed a SVN to investigate the correlation between aerosolized drug concentration and distance from a patient. The test drug administered was 2.5 mL of salbutamol sulfate, diluted in a 1:1 ratio with sterile normal saline for testing purposes. The primary goal was to simulate a scenario in which a patient sat by the bedside and inhaled the medication. Aerosols were sampled at distances of 0.1 (n = 3), 1 (n = 4), 1.6 (n = 4), and 3 (n = 4) meters from the SVN. Air sampling was conducted using a three-piece cassette containing a polytetrafluoroethylene filter. The sampling setup was positioned 1.2 meters above the ground, with a sampling flow rate of 10 L min–1. Throughout the sampling period, the air conditioner, doors, and windows remained closed, and changes in environmental temperature and RH were monitored. Filter samples were extracted using sterile deionized water, followed by centrifugation at 150 rpm for 10 minutes. Drug concentration analysis was performed using spectrophotometry at a wavelength of 276 nm.

 
2.3 Statistical Analysis

Statistical analyses were conducted using the SPSS version 28.0 software (SPSS, Chicago, Illinois, USA), and graphical representations were created using GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, USA). The significance level was set at P < 0.05. In addition to descriptive statistical analysis, we utilized the Kruskal-Wallis test and Mann-Whitney U test to compare differences in the concentration of aerosolized drugs at various distances from the SVN. Furthermore, Spearman’s correlation analysis was employed to assess the relationships between indoor air quality indices and concentrations of aerosolized drugs.


3 RESULTS AND DISCUSSION


 
3.1 Air Quality Assessment in the PICU

This study reveals that the average temperature and RH in the PICU were 22.81°C and 53.88%, respectively (Fig. 2). Additionally, the concentrations of CO2 (750.88 ppm), PM10 (4.59 µg m–3), and PM2.5 (1.99 µg m–3) all met the indoor air quality standards (CO2: 1,000 ppm, PM10: 75 µg m–3, PM2.5: 35 µg m–3) set by Taiwan’s MOENV (TMOENV, 2023). However, the average concentration of TVOCs (1,067.88 ppb) exceeded the indoor air quality standard value of 560 ppb by approximately twofold (Fig. 2). It could be related to the frequent use of alcohol and other cleaning agents for environmental disinfection. Long-term exposure to these VOCs may cause symptoms such as dizziness, headache, drowsiness, weakness, and chest tightness (Health Canada, 2023), thereby affecting the work efficiency of medical staff and potentially reducing the quality of medical care. Analysis of the trend chart demonstrates that CO2 concentrations gradually decreased after 8 o'clock in the evening, followed by a gradual increase after 6 o'clock in the morning. TVOC concentration followed a similar trend, with a slight rise at 5 o'clock in the morning. Moreover, the concentration trends of PM10, PM2.5, PM1, and PM0.01-0.03 in the PICU exhibited similarities. Notably, peak changes in these PM concentrations occurred at 8 a.m., 4 p.m., and midnight.

 Fig. 2. The trend of air quality in the pediatric intensive care unit.Fig. 2. The trend of air quality in the pediatric intensive care unit.

In this study, the CO2 concentration fluctuated with time, and after 10 o'clock at night, the value was significantly lower than during the day. This could be attributed to fewer treatment items and reduced movement of medical staff during the night, along with the absence of cleaning staff to perform cleaning and disinfection activities. A similar trend with three peaks—namely, at 8 a.m., 4 p.m., and 12 midnight—was observed in the concentrations of PM10, PM2.5, PM1, and PM0.01-0.3. It was speculated that PM concentration was elevated by medical staff during shift changes, when handling instruments, or when moving around. Additionally, the indoor temperature and RH showed no significant change, likely because the hospital utilized a central air conditioning system for ventilation.

In addition, the study found that the mean (range) frequency of inhaler uses and drug concentrations measured in the PICU within the sampling days were as follows: 9 (0–19) times and 0.05 pg m–3 of terbutaline, 3 times (0–13) and 0.063 pg m–3 of Combivent®, 15.75 (0–30) times and 0.009 pg m–3 of acetylcysteine, 4.13 (0–14) times and 0.004 pg m–3 of colistin, and 5.25 (0–13) times and 0.008 pg m–3 of epinephrine. This study explored the correlation between drug concentration in the air and air quality indices in the PICU. The results found that only the concentration of acetylcysteine in the air was positively associated with RH (rs = 0.783, P = 0.022) and CO2 concentration (rs = 0.747, P = 0.033), while a significant negative correlation was found between the concentration of acetylcysteine and PM10 concentration (rs = –0.759, P = 0.029) (Table 1). Other drug concentrations in the air showed no correlation with air quality indices and the frequency of inhaler use.

Table 1. Associations between air quality indices and aerosolized drug concentration in the pediatric intensive care unit.

During the study period, the concentrations of colistin and acetylcysteine drugs in the air detected in the PICU were extremely low. It is speculated that the low concentrations were possibly due to the aerosolized drugs exhaled by the patients being filtered by the breathing circuit filters. Additionally, the spraying frequency of aerosolized drugs was not found to be correlated with the drug concentration in the air of the PICU. The lack of correlation could be attributed to both the low spraying frequency and the dilution of aerosolized drug concentrations by the air conditioning system. Moreover, a notable finding was the high positive correlation between acetylcysteine and CO2 concentration. This suggests that indoor ventilation conditions can significantly influence drug concentrations in the air. Therefore, maintaining optimal indoor ventilation is crucial to effectively regulating drug concentrations.

 
3.2 Airborne Drug Concentrations at Various Distances from a Simulated Patient

In terms of simulation research, the analytical results showed that the indoor temperature during the experiment ranged from 19.14°C to 24.32°C, while the RH ranged from 61.6% to 88.5%. Additionally, it was found that the aerosolized drug concentrations were not related to the ambient temperature (rs = 0.32, P = 0.24) and RH (rs = –0.22, P = 0.43). To evaluate the relationship between changes in aerosolized drug concentrations and different distances from simulated patients inhaling drugs, the analytical results showed that the drug concentration was 220 pg m–3 (sd = 8.3 pg m–3) at a distance of 0.1 m when patients inhaled drugs from an SVN. The drug concentration decreased as the distance increased (1 m: 32.4 pg m–3, 1.6 m: 4.91 pg m–3, 3 m: 3.76 pg m–3) (Fig. 3). Furthermore, the results showed that the drug concentrations measured at 1 m, 1.6 m, and 3 m away from the SVN were significantly lower than the drug concentrations measured at 0.1 m away from the SVN. Additionally, the drug concentrations measured at 1.6 m and 3 m away from the SVN were also significantly lower than those measured at 1 m away from the SVN. However, there was no difference between the drug concentrations measured at 1.6 m and 3 m away from the SVN.

Fig. 3. Concentration distribution of aerosolized drugs at different distances.Fig. 3. Concentration distribution of aerosolized drugs at different distances.

When using SVN for aerosol therapy in a clinical setting, it is recommended to maintain a gas flow rate between 6 and 10 L min–1. Higher flow rates result in the production of smaller particles, allowing them to disperse over a greater distance (Crowley et al., 2022; Dellweg et al., 2021). This simulation study revealed that in environments without air conditioning, the drug concentration in the air at a distance of 1 m from the SVN was significantly lower than the drug concentration directly measured at the SVN. Furthermore, the drug concentration at 1.6 m and 3 m from the SVN was significantly reduced. Currently, healthcare facilities specify a separation of 1 m between beds in general wards and 1.6 m in intensive care units. These distances are considered relatively safe concerning nearby patient exposure. Moreover, considering the presence of a ventilation system within the hospital, it is plausible to expect lower drug concentrations escaping into the air within the wards. However, caution should still be exercised when in close contact with patients undergoing SVN treatment due to the risk of drug exposure. In such situations, medical staff or family members should consider wearing N95 masks for personal protection. Additionally, installing a HEPA filter at the expiratory limb of the ventilator circuit can provide an added layer of safety. Furthermore, maintaining appropriate ventilation conditions is essential for both general wards and intensive care units to ensure optimal indoor air quality.

 
4 CONCLUSIONS


The study demonstrated that the concentration of TVOCs in the PICU exceeded established standards. A correlation was observed between CO2 concentration and aerosolized drug concentration, emphasizing the importance of vigilant monitoring of ventilation conditions within the environment. Furthermore, during aerosol therapy treatment for patients, it is imperative for medical staff and family members to maintain a safe distance or incorporate a HEPA filter into the ventilator circuit system. This precautionary measure aims to minimize unwarranted exposure and uphold the air quality within the hospital.

 
ACKNOWLEDGMENTS


This work was supported by the Chang Gung Medical Foundation [BMRP441 to GHW]. The authors thank Ms. Pei-Chen Yang for her technical assistance in this study.

 
ADDITIONAL INFORMATION AND DECLARATIONS



Credit Authorship Contribution Statement

HYT: Methodology, Data curation, Writing – original draft. YTT: Methodology, Investigation. YSS: Investigation, Formal analysis. PPP: Investigation, Data curation. GHW: Conceptualization, Methodology, Data curation, Visualization, Writing – review & editing, Funding acquisition

 
Declaration of Competing Interest

The authors declare no conflict of interest.


REFERENCES


  1. Abdelrahman, M.A., Elberry, A.A., Hussein, R.R.S., Abdelrahim, M.E. (2020). Effect of holding chamber as an add-on device on aerosol delivery and fugitive aerosol from different jet nebulizers. J. Pharm. Innovation 15, 73–79. https://doi.org/10.1007/s12247-018-9369-2

  2. Ari, A., Harwood, R., Sheard, M., Alquaimi, M.M., Alhamad, B., Fink, J.B. (2016). Quantifying aerosol delivery in simulated spontaneously breathing patients with tracheostomy using different humidification systems with or without exhaled humidity. Respir. Care 61, 600–606. https://doi.org/10.4187/respcare.04127

  3. Bauer, A., McGlynn, P., Bovet, L.L., Mims, P.L., Curry, L.A., Hanrahan, J.P. (2009). The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir. Care 54, 1488–1492. https://rc.rcjournal.com/content/54/11/1488

  4. Chang, R.Y.K., Kwok, P.C.L., Ghassabian, S., Brannan, J.D., Koskela, H.O., Chan, H.K. (2020). Cough as an adverse effect on inhalation pharmaceutical products. Br. J. Pharmacol. 177, 4096–4112. https://doi.org/10.1111/bph.15197

  5. Clara, P.C., Jerez, F.R., Ramirez, J.B., Gonzalez, C.M. (2023). Deposition and clinical impact of inhaled particles in the lung. Arch. Bronconeumol. 59, 377–382. https://doi.org/10.1016/j.​arbres.2023.01.016

  6. Crowley, C., Murphy, B., McCaul, C., Cahill, R., Nolan, K.P. (2022). Airborne particle dispersion by high flow nasal oxygen: An experimental and CFD analysis. PLoS One 17, e0262547. https://doi.org/10.1371/journal.pone.0262547

  7. Delclos, G.L., Gimeno, D., Arif, A.A., Burau, K.D., Carson, A., Lusk, C., Stock, T., Symanski, E., Whitehead, L.W., Zock, J.P., Benavides, F.G., Anto, J.M. (2007). Occupational risk factors and asthma among health care professionals. Am. J. Respir. Crit. Care Med. 175, 667–675. https://doi.org/10.1164/rccm.200609-1331OC

  8. Dellweg, D., Kerl, J., Gena, A.W., Alsaad, H., Voelker, C. (2021). Exhalation spreading during nasal high-flow therapy at different flow rates. Crit. Care Med. 49, e693–e700. https://doi.org/​10.1097/CCM.0000000000005009

  9. Dubus, J.C., Mely, L., Huiart, L., Marguet, C., Le Roux, P., Reseau de Recherche Clinique en Pneumologie, P. (2003). Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundam. Clin. Pharmacol. 17, 627–631. https://doi.org/10.1046/j.1472-8206.2003.00191.x

  10. Failla, M., Biondi, G., Provvidenza Pistorio, M., Gili, E., Mastruzzo, C., Vancheri, C., Crimi, N. (2006). Intranasal steroid reduces exhaled bronchial cysteinyl leukotrienes in allergic patients. Clin. Exp. Allergy 36, 325–330. https://doi.org/10.1111/j.1365-2222.2006.02449.x

  11. He, C., Mackay, I.M., Ramsay, K., Liang, Z., Kidd, T., Knibbs, L.D., Johnson, G., McNeale, D., Stockwell, R., Coulthard, M.G., Long, D.A., Williams, T.J., Duchaine, C., Smith, N., Wainwright, C., Morawska, L. (2017). Particle and bioaerosol characteristics in a paediatric intensive care unit. Environ. Int. 107, 89–99. https://doi.org/10.1016/j.envint.2017.06.020

  12. Health Canada (2023). Volatile organic compounds. Government of Canada. (accessed 18 October 2023).

  13. Hui, D.S., Chan, M.T., Chow, B. (2014). Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. Hong Kong Med. J. 20, 9–13. 

  14. McGrath, J.A., O’Sullivan, A., Bennett, G., O’Toole, C., Joyce, M., Byrne, M.A., MacLoughlin, R. (2019). Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics 11, 75. https://doi.org/10.3390/pharmaceutics11020075

  15. Oilier, K., Leppanen, M., Wu, B.B., Yermakov, M., Newman, N.C., Reponen, T., Grinshpun, S.A. (2019). Inhalation exposure and respiratory protection of home healthcare workers administering aerosolized medications (simulation study). Aerosol Air Qual. Res. 19, 937–944. https://doi.org/​10.4209/aaqr.2018.10.0366

  16. Pedersen, K.M., Handlos, V.N., Heslet, L., Kristensen, H.G. (2006). Factors influencing the in vitro deposition of tobramycin aerosol: a comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J. Aerosol Med. 19, 175–183. https://doi.org/10.1089/jam.2006.19.​175

  17. Ratner, P.A., Spinelli, J.J., Beking, K., Lorenzi, M., Chow, Y., Teschke, K., Le, N.D., Gallagher, R.P., Dimich-Ward, H. (2010). Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs. BMC Nurs. 9, 15. https://doi.org/10.1186/1472-6955-9-15

  18. Roussel, C., Witt, K.L., Shaw, P.B., Connor, T.H. (2019). Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat. Res. Rev. Mutat. Res. 781, 207–217. https://doi.org/10.1016/j.mrrev.2017.08.002

  19. Saeed, H., Mohsen, M., Fink, J.B., Dailey, P., Eldin, A.S., Abdelrahman, M.M., Elberry, A.A., Rabea, H., Hussein, R.R.S., Abdelrahim, M.E.A. (2017). Fill volume, humidification and heat effects on aerosol delivery and fugitive emissions during noninvasive ventilation. J. Drug Delivery Sci. Technol. 39, 372–378. https://doi.org/10.1016/j.jddst.2017.04.026

  20. Taiwan’s Ministry of Environment (TMOENV) (2023). Taiwan Air Quality Monitoring Network. Taiwan Air Quality Index. (accessed 18 October 2023).

  21. Tsai, R.J., Boiano, J.M., Steege, A.L., Sweeney, M.H. (2015). Precautionary practices of respiratory therapists and other health-care practitioners who administer aerosolized medications. Respir. Care 60, 1409–1417. https://doi.org/10.4187/respcare.03817

  22. Wan, G.H., Lin, H.L., Fink, J.B., Chen, Y.H., Wang, W.J., Chiu, Y.C., Kao, Y.Y., Liu, C.J. (2014). In vitro evaluation of aerosol delivery by different nebulization modes in pediatric and adult mechanical ventilators. Respir. Care 59, 1494–1500. https://doi.org/10.4187/respcare.02999

  23. Yang, S.H., Yang, T.M., Lin, H.L., Tsai, Y.H., Fang, T.P., Wan, G.H. (2018). Size distribution of salbutamol/ipratropium aerosols produced by different nebulizers in the absence and presence of heat and humidification. Pulm. Pharmacol. Ther. 48, 22–27. https://doi.org/10.1016/j.pupt.​2017.10.009 


Share this article with your colleagues 

 

Subscribe to our Newsletter 

Aerosol and Air Quality Research has published over 2,000 peer-reviewed articles. Enter your email address to receive latest updates and research articles to your inbox every second week.

8.3
2023CiteScore
 
 
79st percentile
Powered by
Scopus
 
   SCImago Journal & Country Rank

2023 Impact Factor: 2.5
5-Year Impact Factor: 2.8

Aerosol and Air Quality Research partners with Publons

CLOCKSS system has permission to ingest, preserve, and serve this Archival Unit
CLOCKSS system has permission to ingest, preserve, and serve this Archival Unit

Aerosol and Air Quality Research (AAQR) is an independently-run non-profit journal that promotes submissions of high-quality research and strives to be one of the leading aerosol and air quality open-access journals in the world. We use cookies on this website to personalize content to improve your user experience and analyze our traffic. By using this site you agree to its use of cookies.